SecBot SecBot
PRESS-RELEASE ·Filed Jul 2, 2026

MGNX

MacroGenics, Inc.
BULLISH
Impact 6/10
Horizonimmediate Processed4mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

The divestiture strengthens MacroGenics' balance sheet and focuses resources on R&D. Monitor pipeline data readouts and potential partnerships, especially for lorigerlimab and TZIELD, as key catalysts.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.71
T+0 close · Jul 2, 2026 · via day close
Latest settled
−19.32%
T+60 · $3.80
Vs SPY
−22.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 2 $4.71entry
  2. T+1 · 4mo ago −2.97%α −3.85% · $4.57
  3. T+5 · 4mo ago −2.97%α −3.90% · $4.57
  4. T+20 · 4mo ago −19.75%α −19.33% · $3.78
  5. T+60 · 7w ago −19.32%α −22.33% · $3.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitioning to an asset-light R&D model and securing cash to fund its pipeline. The deal includes a supply agreement for continued production support.

Key Financial Metrics

Deal Value
$122.5M

Key Facts

  • Sale of GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million
  • Approximately 140 employees transferred to Bora
  • Supply agreement signed for process development and production for MacroGenics' pipeline

Financial Impact

Proceeds of $122.5 million before expenses represent about 42% of market cap, providing significant cash runway.

cashoperating costs

Risk Factors

  • Dependence on Bora for manufacturing could create supply chain risk
  • Execution risk in transitioning to outsourced manufacturing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3321364

Track record

21 reports on MGNX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
  3. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
  4. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  7. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  9. Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
  10. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026